Latest updates from the phase III STARGLO trial: 2L and 3L+ data

Lymphoma Hub
15/10/2025 3 min
Latest updates from the phase III STARGLO trial: 2L and 3L+ data

Listen "Latest updates from the phase III STARGLO trial: 2L and 3L+ data "

Descargar episodio Ver en sitio original

Episode Synopsis

The Lymphoma Hub was pleased to speak to Charles Herbaux, University of Montpellier, FR. Herbaux discussed the latest updates from the phase III STARGLO trial (NCT04408638), with a focus on second-line (2L) and third-line+ (3L+) data. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

More episodes of the podcast Lymphoma Hub

ASH 2025 | Key highlights in lymphoma and CLL 22/12/2025
ASH 2025 | Latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL 18/12/2025
What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL? 17/12/2025
ASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) vs R2 alone for R/R FL 11/12/2025
ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL 10/12/2025
ASH 2025 | Epcoritamab for R/R DLBCL: Results from EPCORE NHL-6, by race and ethnicity 10/12/2025
Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial 05/12/2025
What factors influence BTKi + BCL-2i treatment selection for patients with CLL? 05/11/2025
Symposium | Customizing therapy for MCL: Q&A 04/09/2025
Symposium | Current therapies for MCL and their combinations 03/09/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA